- Home
- TLSA vs MAIA Comparison
TLSA vs MAIA Comparison
Compare TLSA & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLSA
- MAIA
- Stock Information
- Founded
- TLSA 2013
- MAIA 2018
- Country
- TLSA United Kingdom
- MAIA United States
- Employees
- TLSA N/A
- MAIA N/A
- Industry
- TLSA Biotechnology: Pharmaceutical Preparations
- MAIA Biotechnology: Pharmaceutical Preparations
- Sector
- TLSA Health Care
- MAIA Health Care
- Exchange
- TLSA Nasdaq
- MAIA Nasdaq
- Market Cap
- TLSA 87.8M
- MAIA 62.4M
- IPO Year
- TLSA 2000
- MAIA 2022
- Fundamental
- Price
- TLSA $1.20
- MAIA $2.82
- Analyst Decision
- TLSA
- MAIA
- Analyst Count
- TLSA 0
- MAIA 0
- Target Price
- TLSA N/A
- MAIA N/A
- AVG Volume (30 Days)
- TLSA 145.8K
- MAIA 60.0K
- Earning Date
- TLSA 05-10-2024
- MAIA 11-05-2024
- Dividend Yield
- TLSA N/A
- MAIA N/A
- EPS Growth
- TLSA N/A
- MAIA N/A
- EPS
- TLSA N/A
- MAIA N/A
- Revenue
- TLSA N/A
- MAIA N/A
- Revenue This Year
- TLSA N/A
- MAIA N/A
- Revenue Next Year
- TLSA N/A
- MAIA N/A
- P/E Ratio
- TLSA N/A
- MAIA N/A
- Revenue Growth
- TLSA N/A
- MAIA N/A
- 52 Week Low
- TLSA $0.41
- MAIA $0.82
- 52 Week High
- TLSA $1.74
- MAIA $5.99
- Technical
- Relative Strength Index (RSI)
- TLSA 65.44
- MAIA 50.98
- Support Level
- TLSA $0.83
- MAIA $2.36
- Resistance Level
- TLSA $0.92
- MAIA $2.72
- Average True Range (ATR)
- TLSA 0.09
- MAIA 0.22
- MACD
- TLSA 0.03
- MAIA 0.02
- Stochastic Oscillator
- TLSA 84.52
- MAIA 72.28
About TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in the developing transformative therapies for neurodegenerative and lung diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company. The company develops targeted immunotherapies for cancer. The company is an immune-oncology company, focused on the development of first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. The company's program is THIO, a potential cancer telomere-targeting agent in clinical development for the treatment of telomerase-positive cancer cells.